Across TCGA pan-cancer cohorts, TMEM50A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM50A data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMEM50A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM50A expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC and GBM are the cancer types where TMEM50A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.230	1.000	.038	6	view →
GBM	OS	Median	All	0.592	0.285	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TMEM50A tumor-vs-normal RNA expression · all TMEM50A data types